TCM
DGX icon

Tuttle Capital Management’s Quest Diagnostics DGX Stock Holding History

Tuttle Capital Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,190
Closed -$365K – 205
2020
Q3 		$365K Buy
+3,190
New +$377K 0.25% 84

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FMI
Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tuttle Capital Management's DGX Position: Q4 2020 in Review

Tuttle Capital Management sold out of Quest Diagnostics (DGX) in Q4 2020, closing a stake of 3,190 shares — an estimated $365K sold.

Tuttle Capital Management first reported a position in DGX in Q3 2020 and held it in 1 quarter. The position peaked at $365K in Q3 2020. 811 funds tracked by Wall St. Rank hold DGX as of Q4 2020.

  • Tuttle Capital Management reported no remaining Quest Diagnostics position as of Q4 2020 after selling out during the quarter.
  • Tuttle Capital Management sold 3,190 Quest Diagnostics shares in Q4 2020, an estimated $365K.
  • Tuttle Capital Management first reported a position in Quest Diagnostics in Q3 2020 and held it in 1 quarter.
  • Tuttle Capital Management's Quest Diagnostics position peaked at $365K in Q3 2020.
  • 811 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2020.

Based on Tuttle Capital Management's 13F filing for Q4 2020, filed 20 Jan 2021.